Condition
Neovascularization
Total Trials
5
Recruiting
0
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 2 (1)
Trial Status
Active Not Recruiting2
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT05152524Not ApplicableActive Not Recruiting
Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever
NCT04844619Phase 1Active Not Recruiting
KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial
NCT02486484Phase 2UnknownPrimary
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
NCT00685503Phase 1CompletedPrimary
Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth
NCT00645697CompletedPrimary
Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization
Showing all 5 trials